Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 18/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3115413 | 0.75 | KDM4E (0.58) | MALT1CYP3A4CYP2C9CYP2C19CTSK | |
| SCHEMBL1976461 | 0.75 | HRH3 (0.73) | MALT1CYP3A4CTSK | |
| SCHEMBL3451280 | 0.75 | CTSK (0.58) | MALT1CYP3A4CTSK | |
| SCHEMBL22877055 | 0.74 | MAPK1 (0.76) | MALT1CTSK | |
| SCHEMBL24441137 | 0.74 | MALT1 (1.00) | MALT1CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL24441136 | 0.74 | MALT1 (1.00) | MALT1CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL19174443 | 0.73 | CTSK (0.60) | MALT1CYP3A4CTSK | |
| SCHEMBL29191323 | 0.73 | KDM4E (0.61) | MALT1CYP3A4CYP2C9CYP2C19CTSK | |
| SCHEMBL30823266 | 0.73 | KDM4E (0.61) | MALT1CYP3A4CYP2C9CYP2C19CTSK | |
| SCHEMBL18607635 | 0.72 | IDH1 (0.57) | MALT1KCNH2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| CN-101193868-A | Pyrimidine derivatives for the treatment of GABA B mediated nervous system disorders | NOVARTIS AG (CH) | 2008-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | DPYD, NUDT1, HPRT1 | MALT1 4573/4885CYP3A4 1078/4885CYP2C9 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.